drugset / Trial / NCT04621227

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

NCT04621227

Phase 1 Completed 16 enrolled Pfizer
NaCrossoverOpen-labelOther

Summary

A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Timeline

Start
2020-12-15
Primary completion
2021-05-13
Completion
2021-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Danuglipron Small molecule 120 mg
Subject Danuglipron Small molecule 200 mg
Subject Midazolam Small molecule 2 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral

Indications